Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing
Open Access
- 1 March 2014
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 50 (4), 793-800
- https://doi.org/10.1016/j.ejca.2013.11.030
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domainBlood, 2013
- Routine performance and errors of 454 HLA exon sequencing in diagnosticsBMC Bioinformatics, 2013
- BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationshipsBlood, 2013
- The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemiaHaematologica, 2012
- BCR‐ABL1 kinase domain mutations: Methodology and clinical evaluationAmerican Journal of Hematology, 2012
- The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemiaBlood, 2011
- BCR-ABL Truncation due to Premature Translation Termination as a Mechanism of Resistance to Kinase InhibitorsActa Haematologica, 2009
- An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Chronic Myeloid Leukemia Patients Undergoing Kinase Inhibitor TherapyThe Journal of Molecular Diagnostics, 2008
- Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemiaLeukemia, 2008
- High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutationsLeukemia, 2007